Bender Robert & Associates’s Summit Therapeutics SMMT Stock Holding History

Bender Robert & Associates’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-11,496	Closed	-$205K	–	46
2024 Q4	$205K	Buy	+11,496	New	+$223K	0.05%	41
2024 Q1	–	Sell	-24,059	Closed	-$62.8K	–	49
2023 Q4	$62.8K	Hold	24,059	–	–	0.02%	49
2023 Q3	$45K	Hold	24,059	–	–	0.01%	46
2023 Q2	$60.4K	Buy	24,059 +10,000	+71%	+$18.3K	0.02%	49
2023 Q1	$24.6K	Buy	+14,059	New	+$38.3K	0.01%	53
2022 Q4	–	Sell	-14,059	Closed	-$17K	–	51
2022 Q3	$17K	Hold	14,059	–	–	0.01%	54
2022 Q2	$14K	Buy	+14,059	New	+$19.7K	0.01%	55
2021 Q2	–	Sell	-14,059	Closed	-$83K	–	52
2021 Q1	$83K	Buy	+14,059	New	+$90.7K	0.03%	56

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bender Robert & Associates's SMMT Position: Q1 2025 in Review

Bender Robert & Associates sold out of Summit Therapeutics (SMMT) in Q1 2025, closing a stake of 11,496 shares — an estimated $205K sold.

Bender Robert & Associates first reported a position in SMMT in Q1 2021 and held it in 8 quarters. The position peaked at $205K in Q4 2024. 212 funds tracked by Wall St. Rank hold SMMT as of Q1 2025.

Bender Robert & Associates reported no remaining Summit Therapeutics position as of Q1 2025 after selling out during the quarter.
Bender Robert & Associates sold 11,496 Summit Therapeutics shares in Q1 2025, an estimated $205K.
Bender Robert & Associates first reported a position in Summit Therapeutics in Q1 2021 and held it in 8 quarters.
Bender Robert & Associates's Summit Therapeutics position peaked at $205K in Q4 2024.
212 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2025.

Based on Bender Robert & Associates's 13F filing for Q1 2025, filed 18 Apr 2025.